FDA 483 - Hanmi Pharma Co., Ltd - August 02, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Hanmi Pharm. Co. Ltd. in Pyeongtaek, Gyeonggi, South Korea, a drug substance manufacturer, revealed two significant observations. The firm failed to perform complete analysis of procured materials at appropriate intervals and did not comprehensively test for contamination. Additionally, the company did not fully follow written procedures for monitoring processing steps, specifically failing to thoroughly and timely evaluate quality events and define change effectiveness parameters for a CAPA.
ID · 6c69e1da-cd6f-4ea9-9cd8-879ae9ac5cd9